A new cyber-archaeology research center in the Qualcomm Institute at UC San Diego has received data on 18,500 archaeological sites under a new partnership between the center and the Israel Antiques Authority.
Cancer immunology is based upon boosting the body’s own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.
The Alfred P. Sloan Foundation has selected two UC San Diego faculty for Sloan Research Fellowships in 2016. This year’s recipients at UC San Diego are Charles Sprenger, associate professor of economics and strategy, Rady School of Management and the Department of Economics, and Julio Barreiro, assistant professor of physics, Department of Physics.
Cognitive and functional recovery after a stroke or traumatic injury requires intense rehabilitative therapy to help the brain repair and restructure itself. New findings by researchers at University of California, San Diego School of Medicine report that not only is rehabilitation vital but that a longer, even more intense period of rehabilitation may produce even greater benefit.
Ten teams of innovative students at UC San Diego have been awarded proof-of-concept funding to validate the product concepts behind their innovative projects.
Researchers at University of California, San Diego School of Medicine have discovered that HIV infection of human immune cells triggers a massive increase in methylation, a chemical modification, to both human and viral RNA, aiding replication of the virus. The study, published February 22, 2016 in Nature Microbiology, identifies a new mechanism for controlling HIV replication and its interaction with the host immune system.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
